ARTICLE | Clinical News

SGN-CD19A: Additional Phase I data

February 2, 2015 8:00 AM UTC

Interim data from 51 evaluable patients with relapsed or refractory B cell NHL in an open-label, dose-escalation, U.S. Phase I trial showed that 0.5-6 mg/kg IV SGN-CD19A every 3 weeks led to an ORR of...